New to Meducation?
Sign up
Already signed up? Log In

Category

Preview
0
7

Delay of surgery for melanoma common among Medicare patients

In a study that included more than 32,000 cases of melanoma among Medicare patients, approximately 1 in 5 experienced a delay of surgery that was longer than 1.  
medicalnewstoday.com
about 5 years ago
Preview
0
7

Study demonstrates new noninvasive gene expression profile test predicts melanoma risk more accurately than AJCC online predictor tool

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment, has announced study results demonstrating that its DecisionDx-Melanoma™ gene expression profile...  
medicalnewstoday.com
about 5 years ago
Preview
0
10

Melanoma prognosis affected by number of tumor cells spread to sentinel lymph nodes

Cancer cell spread to the sentinel node - the lymph node to which cancer cells are most likely to spread from a primary tumor - is a risk factor for melanoma death.  
medicalnewstoday.com
about 5 years ago
Preview
0
8

Epigenomic changes play an important role during the progression of melanoma

KU Leuven researchers have zeroed in on what makes cancer cells in melanoma so aggressive. They also succeeded in taming the effect in cell cultures.  
medicalnewstoday.com
about 5 years ago
Preview
0
7

Can cancer vaccines prolong survival?

Therapeutic anti-cancer vaccines developed to treat metastatic disease such as advanced prostate cancer or melanoma rarely have a noticeable effect on the tumor but have been associated with a...  
medicalnewstoday.com
about 5 years ago
Preview
0
4

Deadly skin cancer much more common in today's seniors

British people aged 65 and over are seven times more likely to develop malignant melanoma than seniors from 4 decades ago, partly due to the rise of cheap all-inclusive holidays.  
medicalnewstoday.com
about 5 years ago
Preview
0
2

Personalized vaccine shows promise against melanoma recurrence

Encouraging results from a 'first-in-people' trial have led the FDA to approve the phase 1 clinical study of an experimental, personalized anticancer vaccine.  
medicalnewstoday.com
about 5 years ago
Preview
0
3

Rutgers Cancer Institute of New Jersey research shows gene removal may aid melanoma treatment

Nearly 10,000 deaths from melanoma - the deadliest of all skin cancers - occurred in the U.S. last year, according to the National Cancer Institute.  
medicalnewstoday.com
about 5 years ago
Preview
0
8

UCLA researchers combine benefits of immunotherapy and cancer-targeted treatment in triple combo drug for melanoma

Results of a new study by UCLA researchers has found that a new triple combination drug therapy shows promising signs of more effectively controlling advanced melanoma than previous BRAF + MEK...  
medicalnewstoday.com
about 5 years ago
Preview
0
9

Macrophages may play critical role in melanoma resistance to BRAF inhibitors

With targeted therapies no longer viewed as a 'magic bullet' for cancer treatment, this study suggests that macrophages could be a new therapeutic target for patients with...  
medicalnewstoday.com
about 5 years ago
Preview
0
8

Gene mutations may predict melanoma response to immunotherapies

Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer...  
medicalnewstoday.com
about 5 years ago
Preview
0
2

Nodal alone does not produce anti-cancer effects

Metastatic melanoma is the leading cause of skin cancer deaths in the United States; once melanoma has spread (metastasized), life expectancy for patients can be dramatically shortened.  
medicalnewstoday.com
about 5 years ago
Preview
0
5

KEYTRUDA (pembrolizumab) is first medicine to be made available to patients through U.K. Early Access to Medicines Scheme (EAMS) for advanced melanoma

Merck, known as MSD outside the United States and Canada, has announced that the company's anti-PD-1 therapy, pembrolizumab, which is marketed in the U.S.  
medicalnewstoday.com
about 5 years ago
Preview
0
1

Radiation plus immunotherapy combo revs up immune system to better attack melanoma, Penn study suggests

Radiation plus ipilimumab shrank tumors in some patients, but preclinical data suggests adding second immunotherapy will elicit response in resistant patientsTreating metastatic...  
medicalnewstoday.com
about 5 years ago
Preview
0
15

Myriad publishes myPath Melanoma pivotal validation study

Myriad Genetics, Inc. has announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath Melanoma test is highly effective...  
medicalnewstoday.com
about 5 years ago
Preview
0
4

Gene alterations in melanoma may predict immunotherapy outcomes

Among melanoma patients who were treated with immunotherapies, those whose tumors had mutations in the gene NRAS had better response and treatment outcomes than those whose tumors did not have...  
medicalnewstoday.com
about 5 years ago
Nci 150420 metastatic melanoma 800x600
0
10

One in Five Melanomas Undetectable After Immune Drug Combo

Combining nivolumab and ipilimumab also resulted in nearly a quarter of patients having their advanced melanoma become undetectable. Experts are excited.  
medscape.com
about 5 years ago
Preview
0
8

Paradigm Shift: Anti-PD-1 Keytruda Tops Yervoy for Melanoma

The newer drug, pembrolizumab, is a better first-line therapy than ipilimumab for advanced melanoma.  
medscape.com
about 5 years ago
Preview
0
3

Lymph node biopsy followed by lymph node dissection for localised skin cancer | Cochrane

Melanoma arises from the uncontrollable growth of cells in the skin that produce the pigment melanin; it is the leading cause of skin cancer-associated mortality. In invasive melanoma, the tumour has infiltrated into the dermis (a deep layer in the skin).  
cochrane.org
about 5 years ago